

HOLLINGS

The Newsletter of Hollings Cancer Center
Medical University of South Carolina

HORIZONS

Fall 2014

LEADING THE WAY

News of our National Cancer Institute (NCI) Designation renewal was greeted this summer with a great deal of pride, causing us to reflect on the many accomplishments of recent years at Hollings Cancer Center and the strong leadership team that has led us to this point.



From the Director



Leadership has been defined as the ability to translate vision into reality. Working at Hollings Cancer Center (HCC), I am inspired every day by the leaders around me. We have cancer researchers and clinicians who are making headway toward unravelling the mysteries of cancer and developing better therapies. As a cancer center, we are leading the way across South Carolina to prevent cancer, provide better treatment, improve access to care, and find cures. Hollings researchers are making advances that will affect cancer care and outcomes in a far-reaching manner as well.

As we highlight the leadership around us, we extend our enormous gratitude to Dr. Andrew S. Kraft, our HCC Director during the past 10 years. Building on the foundation he inherited, Dr. Kraft helped put into place the strong infrastructure and leadership team that will guide Hollings into a very promising future. He led the effort to recruit nationally-acclaimed researchers and clinicians who are working with our long-standing faculty to give our center and our patients the very best, and helped to develop programs that are gaining national attention. Dr. Kraft also guided our center in achieving NCI Designation and through our recent renewal. We wish him well as he embarks on his new role as the Director of the University of Arizona Cancer Center and look back with pride on the many accomplishments that were achieved during his tenure here.

As a new chapter at HCC Center unfolds, the foundation is firm, our leadership abilities robust, and the future very bright. I look forward to working with our team and the community at large as we lead the way in changing what's possible in cancer care.

Anthony J. Alberg, PhD, MPH
Interim Director

Currently held by only 68 cancer centers in the country, NCI Designation “recognizes centers around the country that meet rigorous criteria for world-class, state-of-the-art programs in multidisciplinary cancer research.” Many have observed that Hollings has been on an upward trajectory, expanding our horizons and making advances on clinical and research fronts. As we look toward the future, we do so with appreciation for the many accomplishments and leaders that have positioned us to reach even higher.

A Decade of Excellence and Growth

In the last ten years, we have seen much change and growth at Hollings Cancer Center (HCC). Dr. Andrew S. Kraft joined Hollings as Director in 2004, and in 2009, we successfully attained NCI Designation for the first time. Achieving NCI Designation involved the development and recruitment of faculty and staff, broadening of research programs, increased funding, and expanding our facilities. Over this ten year span, significant and strategic recruitment efforts have put into place a



top-notch leadership team for the cancer center and brought in clinicians and researchers who are leaders across the MUSC campus and nationally. These new faculty members joined the outstanding team that has diligently worked to build Hollings Cancer Center since its inception in 1993, and the HCC now boasts 122 cancer scientists along with another 50 oncology specialists, more than doubling our numbers in the past ten years alone.

Growth has led to the need for expanded facilities as well. In the last ten years, Hollings facilities have grown dramatically to accommodate increasing needs on the clinical and research fronts. Along with the addition of clinical and research space in the HCC building, the construction of the Clyburn Research Center, encompassing the Bioengineering and Drug Discovery Buildings, enabled significant expansion of cancer research spaces. Outpatient clinical space grew by over 60 percent, and research space has more than doubled in the last ten years, bringing the total space that HCC occupies to more than 270,000 square feet at MUSC.

Hollings has also grown in funding. In 2004, our cancer research funding was roughly \$27 million; today, our annual cancer research funding portfolio stands at over \$42 million. This funding has led to important discoveries — in just the last four years, Hollings Cancer Center scientists published 722 articles in peer-reviewed publications,

NCI·CC

A Cancer Center Designated by the National Cancer Institute



Leaders Among Us

Cancer centers achieve excellence and truly make a difference when effective leaders are at the helm. At Hollings Cancer Center, we have leaders all around us, leading within our institution and in the greater community of cancer researchers. Acknowledging that it's impossible to list everyone, we highlight a few of our stars in recent years.

LEADING AT HOLLINGS AND MUSC



David J. Cole, MD

The MUSC Board of Trustees recently named **David J. Cole, MD**, a leading oncology surgeon and researcher at the Hollings Cancer Center, president of the university and its affiliated medical centers. Along with his research and clinical roles with the HCC, Dr. Cole most recently served MUSC as president of MUSC Physicians and as Chair of the Department of Surgery.




Zihai Li, MD, PhD

The leader of the Cancer Immunology Program at Hollings Cancer Center, **Zihai Li, MD, PhD**, also serves as Chair of the Department of Microbiology & Immunology for MUSC. He holds the Sally Abney Rose Endowed Chair in Stem Cell Biology & Therapy, SmartState Center of Economic Excellence. His research team has made significant contributions to understanding the immunological properties of heat shock proteins in cancer immunotherapy and immune tolerance.



Steven L. Carroll, MD, PhD

Steven L. Carroll, MD, PhD, is Chair of the Department of Pathology & Laboratory Medicine for MUSC. As a cancer researcher, he is focused on determining what molecular abnormalities are responsible for the development of schwannomas, plexiform neurofibromas and malignant peripheral nerve sheath tumors and using this information to develop effective new treatments for these neoplasms.



Philip H. Howe, PhD

Philip H. Howe, PhD, is Professor and Chair of MUSC's Biochemistry & Molecular Biology Department and holds the Hans & Helen Koebig Chair in Oncology. As HCC's Associate Director for Basic Sciences for the last two years, Dr. Howe played a critical role in identifying and shaping the trajectory of new programmatic scientific directions. He has been responsible for ensuring that the basic science efforts at Hollings are growing, well-matched to the mission, and integrated into all HCC programs.



helping to advance cancer research on many fronts.

In patient care, Hollings Cancer Center has grown by over 60 percent in ten years. We saw approximately 1836 new patients per year in 2004, and in 2014, that number will exceed 3000. Hollings' Blood & Bone Marrow Transplant program just reached a huge milestone as well, performing our 1500th bone marrow transplant. The program now performs an average of 120 transplants per year.

Along with caring for an increasing number of patients, we have made great strides in identifying and obtaining the latest treatment for our patients. In a decade, we have gone from enrolling just over 40 patients per year to therapeutic clinical trials to nearly 400 patients per year in 2013, and we now have a well-established Phase I Clinical Trials program. Earlier this year, HCC physicians and scientists completed accrual to a first-in-class, first-in-human Phase I clinical trial, typically only seen at larger cancer centers such as MD Anderson or Memorial Sloan Kettering. Therapies developed right here are being made available to HCC patients.

Working to fulfill our mission as a cancer center that serves all of the citizens of South Carolina, our statewide outreach also continues to grow. Our Mobile Health Unit now sees approximately 2,000 people per year for mammograms, and skin, prostate, and cervical cancer screenings. Notably, over 80 percent of these patients report that they likely would not have sought treatment without the access afforded to them through the mobile unit.

Starting in 2006, we established a Cancer Control program that has grown and matured significantly, fostering research into the causes and behaviors that



can lead to cancer and affect outcomes. The development of this program has led to the HCC being recognized internationally for expertise in tobacco control and as a leader in health disparities research.

As we look toward our next decade at Hollings and beyond, it is with the assuredness that we are on very solid ground, but also the realization that there is much more to be done. Building on the progress made by so many over the course of our history, Hollings Cancer Center remains committed to leading the way – at MUSC, in our state, and in the U.S. - in changing what's possible for all cancer patients.



LEADERS ON THE NATIONAL FRONT

Gerard A. Silvestri, MD, MS, has been elected as the President of the American College of Chest Physicians for 2017. He will serve a four year appointment as President-Designate 2015, President-Elect 2016, President 2017, and Immediate Past President 2018. The American College of Chest Physicians has 18,700 members representing more than 100 countries around the world and is the largest international organization for chest medicine specialists in the world. At MUSC, Dr. Silvestri is the George C. & Margaret M. Hillenbrand Endowed Professor, Division of Pulmonary and Critical Care Medicine, and serves as Vice-Chair of Medicine for Faculty Development. His research interests focus on developing new screening, diagnostic and prognostic approaches for lung cancer.



Gerard A. Silvestri, MD, MS


Chanita Hughes-Halbert, PhD,

currently serves as an appointee of President Barack Obama on the NCI Board of Scientific Advisors. In this role, she and fellow board members provide scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the NCI's extramural research programs, and concept review of extramural program initiatives. At the HCC, Dr. Hughes-Halbert holds the AT&T Distinguished Endowed Chair in Cancer Equity, SmartState Center of Economic Excellence, serves as Program Leader for the HCC Cancer Control Program, and is a Professor of Psychiatry & Behavioral Sciences in the College of Medicine. Dr. Hughes-Halbert has made several seminal contributions to the fields of cancer control, minority health, and health disparities.



Chanita Hughes-Halbert, PhD

Kenneth D. Tew, PhD, currently serves on the editorial boards of ten scientific journals and is associate editor for the *Journal of Pharmacology and Experimental Therapeutics*, senior editor for *Cancer Research*, and a past co-serial editor for *Advances in Cancer Research*. He is a fellow of the American Association for the Advancement of Science (AAAS), chair of the Section of Pharmaceutical Sciences AAAS, and served as Chair of the Drug



Kenneth D. Tew, PhD

Discovery and Development Section of the American Society of Pharmacology and Experimental Therapeutics (ASPET) in 2011-2013. Dr. Tew is Program Leader for the Developmental Cancer Therapeutics Research Program at the HCC, Professor and Chair of the Department of Cell & Molecular Pharmacology at MUSC, and holds the John C. West Endowed Chair in Cancer Research, which is supported by the South Carolina SmartState Center of Excellence in Translational Cancer Therapeutics.

HOLLINGS RESEARCHERS CONTRIBUTE TO SURGEON GENERAL'S REPORT

When the U.S. Surgeon General recently released *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General* marking the 50 years since the original landmark 1964 report, Hollings Cancer Center researchers played a prominent role in the report, offering important new information related to the effects of smoking for cancer patients undergoing treatment.



The original Surgeon General's Report concluded that smoking caused lung cancer and laryngeal cancer in men. Since then, several additional cancer sites have been added to the list, and today, tobacco use accounts for approximately one-third of all cancer deaths annually.

Of note in the new report is the finding that smoking is now also causally associated with adverse outcomes in cancer patients undergoing treatment. The report concluded that the evidence is sufficient to infer a causal relationship between cigarette smoking and risk of death from cancer and other causes, and risk for getting another cancer in patients undergoing treatment and survivors. The scientific community has known for fifty years that smoking was linked to the development of cancer; with the new evidence presented in the 2014 Surgeon General's Report, it is now also clear that ***quitting smoking improves the prognosis of cancer patients.***

Three HCC researchers contributed to the 2014 Surgeon General's Report: Graham W. Warren, MD, PhD, Vice Chair for Research in MUSC's Radiation Oncology Department; Anthony J. Alberg, PhD, Professor of Public Health Sciences and HCC Interim Director / Associate Director of

Population Sciences; and K. Michael Cummings, PhD, Professor of Psychiatry & Behavioral Medicine.

"We have suspected for some time that there was an association between continued use of tobacco and treatment outcomes in cancer patients," commented Dr. Warren. "Now we have conclusive evidence that smoking is bad for virtually all cancer patients and for all types of cancer treatment."

According to Dr. Warren, the evidence presented in this report changes and shapes how physicians will advise patients undergoing treatment going forward. While some have previously not broached the subject of smoking with patients in treatment, Hollings Cancer Center physicians and those across the country are now using these findings to counsel patients that smoking can have a negative effect on their treatment and long-term outcomes.

Dr. Warren added, "These new findings give us one more tool for ensuring that our cancer patients have the best possible outcome."

Tobacco Assessment and Cessation Programs

Armed with the knowledge that smoking both leads to cancer and affects the prognosis of cancer patients while in treatment, the Hollings Cancer Center and MUSC are advancing treatment for all patients by developing novel treatment strategies to help patients quit smoking. Dr. K. Michael Cummings and Dr. Graham W. Warren worked with Dr. Matthew J. Carpenter and several other HCC members to develop a new in-patient clinical tobacco assessment and cessation program as well as a new program available for all cancer patients at the HCC. In the HCC program, cancer patients are screened for tobacco use and automatically referred to a dedicated tobacco cessation program where patients receive evidence-based treatment using biochemical testing, motivational interviewing, behavioral counseling, medications, and follow-up. The inpatient component of this program was recently adopted and will be implemented at other Charleston area hospitals as well. Through the addition of several new faculty, increased research funding, and new clinical infrastructure, the HCC and MUSC are gaining ground as a national leader in tobacco control by paving the way to improved clinical treatment outcomes for patients.

GENOMIC TESTING LEADS TO A MORE TARGETED APPROACH



In June of 2011, Charles Fitch was retired from the Air Force and enjoying the next phase of life when he heard those words no one expects: “You have cancer.” A very fit and active 53-year-old at the time, Fitch thought he was “doing everything right.” Despite all of this, Hollings hematologist/oncologist Robert K. Stuart, MD, explained to Fitch that he had a very aggressive type of leukemia. Thanks to advanced cancer research being done at Hollings Cancer Center and across the country, though, Dr. Stuart was able to offer hope to Fitch and his family.

At the outset, physicians and scientists at Hollings were able to perform genomic sequencing of Fitch’s DNA and determine that he had the “Philadelphia chromosome,” a specific chromosomal abnormality that is associated with chronic myelogenous leukemia and 25 to 30 percent of the adults with acute lymphoblastic leukemia, the type Fitch had. Dr. Stuart explained that this type of diagnosis in years past often did not yield a positive outcome, but newly developed advanced genomic testing allowed the team at Hollings to specifically target Fitch’s cancer in a personalized, very targeted manner.

From Fitch’s initial diagnosis to follow-up care today, Dr. Stuart says the team at Hollings has been able to use this genomic mapping to chart a course for treatment, check progress, and look for recurrence. In 2013, genomic testing led to the detection of a relapse well before it would have been “clinically apparent”,

From Fitch’s initial diagnosis to follow-up care today, Dr. Stuart says the team at Hollings has been able to use this genomic mapping to chart a course for treatment, check progress, and look for recurrence. In 2013, genomic testing led to the detection of a relapse well before it would have been “clinically apparent”, allowing the team to treat it much sooner.

allowing the team to treat it much sooner.

Today, Fitch is enjoying being in remission and expresses deep gratitude for the team at Hollings Cancer Center. “The care here is outstanding. The staff was always there, not afraid to shed a tear or share a laugh, and there was always a hug waiting if I needed it.”

Though Charles Fitch is now more focused on things like competing with Dragonboat Charleston, he explains with a smile that one of his most prized “trophy” is the gold smiley face sticker he earned from Dr. Stuart for being a gold-star patient. Reflecting on his experience as part of the Hollings family, Fitch offers, “From the beginning, we knew this was the right place. I have witnessed true compassion and professionalism, and will always have profound respect and the utmost appreciation to all for the job they do on a daily basis.”

LEADERS (CONTINUED)

Deborah C. Bryant, DNP, RN, HCC’s

Assistant Director of Outreach and Cancer Prevention & Control, was recently awarded the Robert Wood Johnson Foundation Nursing Fellowship. As one of 20 recipients



Deborah C. Bryant, DNP, RN

from across the U.S., she will participate in a three-year leadership development program designed to enhance effectiveness in improving the country’s health care system. Each Fellow receives coaching, education, and other support designed to strengthen their ability to lead teams and organizations that are working to improve health and health care. In 2012, Dr. Bryant was awarded the Robert Wood Johnson Foundation Community Health Leader Award, and in July of 2014, she was a featured speaker at a congressional briefing on Capitol Hill to discuss the rising mortality rates among women in the U.S.

Dr. J. Alan Diehl joins HCC as Associate Director for Basic Sciences

J. Alan Diehl, PhD, has joined Hollings Cancer Center as the HCC Associate Director for Basic Sciences. Dr. Diehl joined us July 1 from the Abramson Family Cancer Research Institute



J. Alan Diehl, PhD

at the University of Pennsylvania to serve as the Smart State Chair in Lipidomics & Pathobiology and as Professor of Biochemistry & Molecular Biology. He earned his PhD from the University of Missouri-Columbia and completed post-doctoral work at St. Jude Children’s Research Hospital. Using state-of-the-art techniques, including genomics, proteomics, and mouse models, Dr. Diehl’s laboratory has identified novel molecular targets essential to the development of new cancer therapies.

■ Gifts Fund Research

BARNWELL FAMILY HONORS DR. ROBERT K. STUART

A reception was held June 27 at Hollings Cancer Center to thank the Doctor and Mrs. William H. Barnwell family and other donors for establishing the Robert K. Stuart, MD, Distinguished Endowed Chair in Hematology/Oncology, and to introduce Xue-Zhong Yu, MD, the first occupant of the chair. One of the country's leading researchers in hematopoietic stem cell therapy, Xue-Zhong Yu, MD, joined the faculty of MUSC in 2013 as a professor in MUSC's Department of Microbiology and Immunology and Department of Medicine. The late Dr. William H. Barnwell, a patient of Dr. Stuart's and a physician himself, chose to establish this chair in honor of the work that Dr. Stuart has done in bone marrow transplant (BMT) medicine at Hollings.



Above: *The Barnwell family gathers with Drs. Stuart and Yu at the reception. Pictured left: Robert K. Stuart, MD (right) introduces Xue-Zhong Yu, MD, as the first occupant of the Robert K. Stuart, MD, Distinguished Endowed Chair in Hematology/Oncology.*



Dr. Stuart, Director of the BMT program, performed MUSC's first BMT in 1987 and supervised the 1500th transplant at MUSC the day of this reception.

The Stuart Chair resides within the SmartState Center of Economic Excellence Program in Cancer Stem Cell Biology and Therapy. As the Smart State Endowed

Chair, Dr. Yu's research is dual. It will identify ways to use the body's blood and marrow stem as treatment for cancer therapy and it will develop therapies targeting cancer stem cells.

CHARLES W. COKER NAMED BOARD MEMBER EMERITUS ON HCC ADVISORY BOARD

At the most recent meeting of the Hollings Cancer Center Advisory Board, long-time board member and former chair Charles W. "Charlie" Coker was named a board member emeritus in recognition of his enduring and significant contributions to the HCC. The retired CEO and Chairman of the Board of Sonoco, Mr. Coker began serving on the Hollings Cancer Center board in 1992 and has made major contributions of both his

time and resources. He and his wife Joan have made significant donations directed toward research, and they have generously funded critical needs such as the HCC Mobile Health Unit and the Smart State Chair in Tobacco Related Malignancies.

We are deeply indebted to Mr. Coker for his long-standing, invaluable contributions and look forward to his continued involvement as Board Member Emeritus.



Charles W. Coker with HCC Board Chair Pamela Lackey

■ Leading Through Action


JEANELLE MCCAIN'S JOURNEY TO HELP OTHERS

When Jeanelle McCain's husband died of melanoma last year, she knew the journey wasn't over. "Will was so involved in public service," she explains of the former state legislator and chief of staff to Governor David Beasley, "I want his legacy to be one of helping others."

Through his experience, Jeanelle learned of the critical need for advanced therapies, and she quickly became immersed in the importance of clinical trials. Because of family associations, the Columbia area residents originally sought care out of state, and as his

close to home: "Our experience at Hollings Cancer Center was so full of compassion and genuine care, I wanted to get involved and help others."

An attorney and former lobbyist, Jeanelle jumped right in, first supporting Hollings' Gourmet & Grapes in February, and soon thereafter, joining the HCC Advisory Board. She and Will's family also wanted to make sure the research that is vital to new therapies continues, so they worked with Hollings Development to establish the Will McCain Melanoma Research Fund to support melanoma research at Hollings. A Legislative



"Will was dedicated to helping South Carolina, and I want to attract the brightest and best to our state. You hear about cancer advances being made across the country. They're making those kinds of discoveries right here."

disease progressed, they identified a promising clinical trial at a major hospital in the northeast. When he was too sick to travel that far, Jeanelle discovered that the same trial was offered just down the road in their home state of South Carolina. "We were thrilled to learn that the latest, most innovative care was available right here at Hollings," she shares.

In the end, Will was too weak to participate in the clinical trial, but Jeanelle walked away committed to let others know they can find cutting-edge treatment for cancer care

Spring Fling fundraiser was held in May to raise funds in memory of the popular public servant, and the fund continues to grow.

Before committing funding, Jeanelle wanted to do some research of her own. She met with Hollings researchers and was impressed by the work and advances in cancer research she saw. She also talked with connections at the NIH and heard that supporting this type of research was a good investment in the future of cancer care. MUSC is fortunate to have researchers like these, she was told.

"Will was dedicated to helping South Carolina, and I want to attract the brightest and best to our state," McCain explains. "You hear about cancer advances being made across the country. They're making those kinds of discoveries right here."

Hollings Director of Development Debbie Bordeau is thankful for the leadership of McCain. "She's giving her time, talent, and expertise in a way that's having a tremendous impact, helping to make Hollings Cancer Center the best place for cancer care for the people of South Carolina," Bordeau adds.

Jeanelle McCain knows her journey has just begun, and she's committed to devoting her resources to helping people affected by cancer here in South Carolina, saying, "Everyone at Hollings tried so hard to give Will every chance. I want to give that hope to others."




WE OFFER MANY THANKS TO HOLLINGS CANCER CENTER BOARD MEMBERS **Tim Walter** and **Russell Holliday**, who have included Hollings Cancer Center in their estate plans to support cancer research. Linda Cox from the Office of Planned Giving recognized their induction into the Legacy Society at the fall meeting of the Advisory Board. For more information about planning a gift to HCC, please contact the Office of Planned Giving at (843) 792-5252 or (800) 810-6872 (MUSC).

FOUNDATION SUPPORTS OVARIAN CANCER RESEARCH

Colleen’s Dream Foundation recently gifted \$10,000 to Hollings Cancer Center to fund ovarian cancer research being conducted by researcher Dr. Hiu Wing Cheung. Colleen’s Dream president Billy Cundiff said, “As an organization, we continue to seek out bright young minds in ovarian cancer research, and Dr. Cheung is one of the best.”

Based in Phoenix, Arizona, Colleen’s Dream Foundation started in 2012 to support research for early detection and improved treatment for ovarian cancer.

“Tony” Cheung, PhD, an Assistant Professor of Pathology & Laboratory Medicine at MUSC, focuses on developing and applying genome-scale tools to characterize cancer genomes and to systematically study the molecular mechanisms underlying cancer development and vulnerabilities. His prior work led to the development of a genome-scale pooled RNA interference screening method, which has been utilized to identify genetic vulnerabilities across one of the most comprehensive panels of cancer cell lines to date.



19TH ANNUAL HOLLINGS CANCER CENTER GOLF TOURNAMENT

Thanks to all who supported the 19th Annual Hollings Cancer Center Golf Tournament at Kiawah Island! We had a great day, and we exceeded our goal of raising \$100,000 to support Hollings Cancer Center! A record number of golfers turned out for a fun day on the Jack Nicklaus-designed Turtle Point Golf Course. We appreciate all of the golfers and sponsors who made the day such a success.



For more information about any Hollings Cancer Center event, please contact the HCC Office of Development at 843-792-1669.



WITH THANKS TO DR. DANIEL J. FERNANDES

Daniel J. Fernandes, PhD, recently retired as the Associate Director of Translational Research at Hollings Cancer Center and Professor of Biochemistry & Molecular Biology in the MUSC College of Medicine. He has served Hollings and MUSC in many leadership roles since joining the faculty in 1993 and is heralded by his colleagues as having made significant contributions in transferring scientific research into clinical applications that will change cancer care for many years. Dr. Fernandes has been continuously funded by the National Cancer Institute for 30 years. His most recent research activities involved the development of a panel of fully human monoclonal antibodies to the tumor antigen, nucleolin, and the formation of an MUSC spinoff company, CharlestonPharma, LLC, to commercialize these antibodies. With many thanks, we wish Dr. Fernandes well in his retirement from MUSC.




■ Special Events

SEVENTH ANNUAL GOURMET AND GRAPES

February 6-8, 2015

Make plans early to experience this celebration of great food and wine, when The Sanctuary at Kiawah Island Golf Resort plays host to a week-end-long immersion into gourmet offerings from award-winning chefs and expertly paired wines from some of the best vineyards around. It is a one-of-a-kind event benefitting cancer research and patient care at Hollings.

Designed to offer something for all palates – from novice to connoisseur – the weekend showcases a variety of events. Among them, this year's Friday evening will feature a special reunion of four extraordinary chefs who have all worked their magic in the kitchen at The Woodlands Inn. Take in one offering, or stay for the weekend. Either way, you'll be sure to leave wanting more.



Tickets may be purchased for the entire weekend or individual events, and sponsorships are available for all events. For details, please visit gourmetandgrapes.com or contact the Hollings Cancer Center Office of Development, 843-792-9335.



A National Cancer Institute
Designated Cancer Center

86 Jonathan Lucas Street • MSC 955
Charleston, South Carolina 29425

Non-Profit
Organization
U.S. Postage
PAID
Charleston, S.C.
Permit #254

Connect with Hollings



Facebook:

<http://facebook.com/muschollings>



Twitter:

<http://twitter.com/muschollings>

Welcome New Hollings Faculty

Gregory A. Cote, MD, MS

Associate Professor
Department of Medicine
Division of Gastroenterology & Hepatology
GI Cancers
From Indiana University

Nancy K. Demore, MD

Professor
Department of Surgery
Breast Surgery
From UNC Chapel Hill

Nathan G. Dolloff, PhD

Assistant Professor
Department of Cell & Molecular Pharmacology
From Penn State University

Theodore S. "Todd" Gourdin, MD

Assistant Professor
Department of Medicine
Division of Hematology/Oncology
GU and GI Cancers
From University of Maryland

Linda E. Kelemen, MSc, ScD

Associate Professor
Department of Public Health Sciences
From Alberta Health Services-Cancer Care

David M. Neskey, MD

Assistant Professor
Department of Otolaryngology
Head and Neck Cancer
From MD Anderson Cancer Center

Jacob A. Klapper, MD

Assistant Professor
Department of Surgery, Thoracic Surgery
From Duke University

Rochelle L. Ringer, MD

Assistant Professor
Department of Surgery
Breast Surgery – MUSC Hilton Head
From Hartford Healthcare Medical Group in Connecticut

Karim Tazi, MD, UD

Instructor
Department of Medicine
Division of Hematology/Oncology
Lung Cancers
From MUSC Fellows Program

Zeke J. Walton, MD

Assistant Professor
Department of Orthopaedics
Musculoskeletal Oncology
From Emory University

John M. Wrangle, MD, MPH

Assistant Professor
Department of Medicine
Division of Hematology/Oncology
Lung Cancer
From The Johns Hopkins University

Yi "Benny" Yang, MD

Assistant Professor
Department of Microbiology & Immunology
From New York University School of Medicine

Hollings Cancer Center
<http://hcc.musc.edu> • 843.792.0700